ERBB2 and breast carcinoma: HER2-targeted antibody-drug conjugates such as trastuzumab-emtansine (T-DM1) or trastuzumab-deruxtecan (T-Dxd) are also used clinically for HER2-positive breast cancers as well as advanced breast cancers characterized by low HER2 levels [7,8].